|1.||Cheung, Nai-Kong V: 2 articles (03/2015 - 07/2003)|
|2.||Cheung, Irene Y: 1 article (03/2015)|
|3.||Kuk, Deborah: 1 article (03/2015)|
|4.||Ostrovnaya, Irina: 1 article (03/2015)|
|5.||LaQuaglia, Michael P: 1 article (07/2003)|
|6.||Kushner, Brian H: 1 article (07/2003)|
|7.||Kramer, Kim: 1 article (07/2003)|
03/01/2015 - "After achieving first remission (n = 163), primary refractory disease (n = 102), or second remission (n = 95), children with stage 4 neuroblastoma received anti-GD2 3F8 antibody immunotherapy. "
05/01/1991 - "To verify that the technique would work in vivo, measurements were made of human neuroblastoma tumors in rats which had been injected with I-124 labeled 3F8 antibody. "
07/01/2003 - "During the period of this study (1995-1999), MSKCC patients with high-risk neuroblastoma received the N7 protocol (dose-intensive chemotherapy, immunotherapy with the anti-G(D2) 3F8 antibody, targeted radiotherapy using 131I-3F8, local radiotherapy) if they had assessable disease, or 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by 13-cis-retinoic acid if they were in remission after treatment elsewhere. "
|1.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|3.||Drug Therapy (Chemotherapy)